Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.2 USD | 0.00% | -4.35% | -67.33% |
Financials (USD)
Sales 2022 | 13.48 | Sales 2023 | 15.77 | Capitalization | 9.96M |
---|---|---|---|---|---|
Net income 2022 | -96M | Net income 2023 | -75M | EV / Sales 2022 | -836,796 x |
Net cash position 2022 | 63.29M | Net Debt 2023 | 15.36M | EV / Sales 2023 | 1,605,487 x |
P/E ratio 2022 |
-0.51
x | P/E ratio 2023 |
-0.13
x | Employees | 25 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.23% |
Latest transcript on Eiger BioPharmaceuticals, Inc.
1 week | -4.35% | ||
Current month | -4.35% | ||
1 month | -3.19% | ||
3 months | -68.18% | ||
6 months | -76.01% | ||
Current year | -67.33% |
Managers | Title | Age | Since |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
James Vollins
CMP | Compliance Officer | 55 | 23-04-12 |
Colin Hislop
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-07-17 | |
Thomas Dietz
CHM | Chairman | 60 | 16-03-21 |
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.00% | 18 M€ | +3.94% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 2.2 | 0.00% | 350 |
24-06-07 | 2.2 | -2.65% | 1,958 |
24-06-06 | 2.26 | -6.22% | 15,587 |
24-06-05 | 2.41 | +4.78% | 3,663 |
24-06-04 | 2.3 | 0.00% | 1,144 |
Delayed Quote OTC Markets, June 10, 2024 at 10:59 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-67.33% | 3.26M | |
+49.41% | 56.95B | |
+41.65% | 40.26B | |
-6.72% | 39.32B | |
-5.96% | 28.37B | |
+12.99% | 26.45B | |
-19.82% | 19.41B | |
+32.35% | 12.54B | |
-0.08% | 12.15B | |
+25.18% | 12.21B |
- Stock Market
- Equities
- EIGR Stock